CRISPR Therapeutics (CRSP) said Monday that preliminary data from an ongoing phase 1/2 trial of CTX112 in relapsed or refractory CD19-positive B-cell malignancies showed that the therapy was well tolerated and induced objective and complete responses at all dose levels.
Five out of the 12 treated patients have achieved responses lasting for more than six months, including one patient whose 6-month response was confirmed after the data cut-off date, according to the company.
"Preliminary data demonstrate that CTX112 has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol," the company said.
CRISPR also said that the Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to CTX112 for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma.
Price: 50.78, Change: -1.55, Percent Change: -2.97
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。